Natera and TransCode Therapeutics to Collaborate on Phase 2a Trial of TTX — MC138 in Colorectal Cancer
For best results when printing this announcement, please click on link below: Natera and TransCode Therapeutics to Collaborate on Phase 2a Trial of TTX-MC138 in Colorectal Cancer TransCode will use Signatera™ to identify MRD-positive patients eligible for enrollment Natera, Inc. ( ) (Nasdaq: NTRA), a global leader in c